Related Experiment Video
Updated: May 5, 2026
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Structure-Based Virtual Screening, ADMET Properties Prediction and Molecular Dynamics Studies Reveal Potential
Shen Li1, Ying Zhou1, Yujuan Yan1
1School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Sun Yat-Sen University, Shenzhen 518107, China.
Abstract:
Mycoplasma pneumoniae pneumonia (MPP) is a frequent cause of community-acquired pneumonia (CAP) in children. The incidence of childhood pneumonia caused by M. pneumoniae infection has been rapidly increasing worldwide. M. pneumoniae is naturally resistant to beta-lactam antibiotics due to its lack of a cell wall. Macrolides and related antibiotics are considered the optimal drugs for treating M. pneumoniae infection. However, clinical resistance to macrolides has become a global concern in recent years. Therefore, it is imperative to urgently identify new targets and develop new anti-M. pneumoniae drugs to treat MMP. Previous studies have shown that deficiencies in HPrK/P kinase or phosphorylase activity can seriously affect carbon metabolism, growth, morphology, and other cellular functions of M. pneumoniae. To identify potential drug development targets against M. pneumoniae, this study analyzed the sequence homology and 3D structure alignment of M. pneumoniae HPrK/P. Through sequence and structure analysis, we found that HPrK/P lacks homologous proteins in the human, while its functional motifs are highly conserved in bacteria. This renders it a promising candidate for drug development. Structure-based virtual screening was then used to discover potential inhibitors among 2614 FDA-approved drugs and 948 bioactive small molecules for M. pneumoniae HPrK/P. Finally, we identified three candidate drugs (Folic acid, Protokylol and Gluconolactone) as potential HPrK/P inhibitors through molecular docking, molecular dynamics (MDs) simulations, and ADMET predictions. These drugs offer new strategies for the treatment of MPP.
Insights
New research identifies the HPrK/P protein as a promising drug target for Mycoplasma pneumoniae pneumonia (MPP). Folic acid, Protokylol, and Gluconolactone show potential as new treatments against this growing infectious disease.
Area of Science:
- Microbiology
- Drug Discovery
- Structural Biology
Background:
- Mycoplasma pneumoniae pneumonia (MPP) is a common childhood infection, with increasing global incidence.
- Existing treatments like macrolides face growing bacterial resistance, necessitating novel therapeutic strategies.
- The HPrK/P protein is crucial for M. pneumoniae's cellular functions and lacks human homologs, making it an attractive drug target.
Purpose of the Study:
- To identify and validate new drug targets for M. pneumoniae infections.
- To screen for potential inhibitors of the M. pneumoniae HPrK/P protein.
- To evaluate candidate drugs for efficacy against M. pneumoniae.
Main Methods:
- Sequence homology and 3D structure analysis of M. pneumoniae HPrK/P.
- Structure-based virtual screening of FDA-approved drugs and bioactive small molecules.
- Molecular docking, molecular dynamics simulations, and ADMET predictions for candidate inhibitors.
Main Results:
- M. pneumoniae HPrK/P exhibits high conservation in bacteria and no homology in humans.
- Virtual screening identified Folic acid, Protokylol, and Gluconolactone as potential HPrK/P inhibitors.
- In silico analyses confirmed the inhibitory potential and drug-like properties of these candidates.
Conclusions:
- The HPrK/P protein is a viable and promising target for developing new anti-M. pneumoniae therapies.
- Folic acid, Protokylol, and Gluconolactone represent potential novel therapeutic agents for treating MPP.
- This study provides a foundation for developing urgently needed treatments against drug-resistant M. pneumoniae infections.
